高压氧治疗对非动脉炎性视网膜中央动脉阻塞的效果(HBOT-CRAO)
该回顾性两中心研究纳入2019年1月至2024年12月诊断的非动脉炎性视网膜中央动脉阻塞患者,发病24小时内到急诊就诊者接受高压氧治疗。17例完成全程高压氧(每日2次×5天,共10次),16例接受部分高压氧(1至7次),32例因超出治疗窗未接受高压氧。三组人口学及临床特征(血管危险因素)无统计学差异。全程高压氧组出院时LogMAR最佳矫正视力显著改善(p=0.01),部分或无高压氧组未见获益;仅1例在高压氧期间出现癫痫发作,其余患者无并发症。作者结论认为高压氧改善完成全程治疗者的视力结局,安全且可考虑用于发病24小时内就诊的患者。
要点
- 非动脉炎性视网膜中央动脉阻塞患者发病24小时内到急诊就诊并完成全程高压氧(每日2次×5天,共10次)者,出院时LogMAR最佳矫正视力显著改善(p=0.01)。
- 接受部分高压氧(1至7次)或未接受高压氧的患者未见视力获益。
- 全程高压氧组、部分高压氧组与未接受高压氧组之间人口学及临床特征(血管危险因素)无统计学差异。
- 仅1例在高压氧治疗期间出现癫痫发作,其余患者无并发症。
- 作者认为高压氧安全,可考虑作为发病24小时内就诊的非动脉炎性视网膜中央动脉阻塞患者的治疗选择。
适用人群与场景
- 两医疗中心2019年1月至2024年12月诊断的非动脉炎性视网膜中央动脉阻塞患者。
- 高压氧提供给发病24小时内到急诊就诊的患者;超出治疗窗者未接受高压氧。
处置流程与药物剂量
- 全程高压氧方案:每日2次,持续5天,共10次高压氧治疗。
- 部分高压氧:1至7次治疗,因患者要求或未见视力改善而中止。
- 未接受高压氧:因超出治疗窗(发病超过24小时)。
研究设计与关键结果
- 回顾性两中心研究,纳入非动脉炎性视网膜中央动脉阻塞患者:全程高压氧组17例,部分高压氧组16例,未接受高压氧组32例。
- 三组人口学及临床特征(血管危险因素)无统计学差异。
- 全程高压氧组出院时LogMAR最佳矫正视力显著改善(p=0.01);部分高压氧组与未接受高压氧组未见获益。
- 仅1例在高压氧治疗期间出现癫痫发作,其余患者无并发症。
证据类型、等级与局限
- 证据类型:回顾性两中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为高压氧安全,可考虑作为发病24小时内就诊的非动脉炎性视网膜中央动脉阻塞患者的治疗选择。
- 作者结论提示高压氧的视力获益仅见于完成全程治疗(每日2次×5天,共10次)者,部分或无高压氧治疗者未见视力结局改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Central retinal artery occlusion (CRAO) is a rare form of acute ischemic stroke that causes severe visual loss, which is a relatively rare emergency but devastating eye condition. There is currently no guideline-endorsed treatment for CRAO. Data on hyperbaric oxygen therapy (HBOT) for CRAO is minimal. We aimed to investigate the benefit of HBOT in patients with non-arteritic CRAO.
METHODS: We conducted a retrospective study from two medical centers that recruited patients with diagnosed non-arteritic CRAO from January 2019 to December 2024. HBOT was offered to CRAO patients who presented to the emergency room within 24 h from symptom onset. Seventeen patients underwent a full course of HBOT (twice a day for five days with a total of 10 HBO treatments). Sixteen CRAO patients received partial HBOT (from 1 to 7 treatments); HBOT was discontinued per patients' request, either due to varied reasons or no noted visual improvement. Thirty-two CRAO patients did not undergo HBOT due to being outside of the treatment window. The primary outcome was visual improvement at the time of discharge. Student's t-test, Mann-Whitney U (Wilcoxon rank sum) test, and Chi-square test were used to compare the change in LogMAR best-corrected visual acuity (BCVA) in patients before and after HBOT.
RESULTS: There was no statistical difference among the three groups in patient demographic and clinical characteristics (vascular risk factors). In the HBOT group, patients who received a full course of HBOT (twice a day for five days) revealed significant visual improvement at discharge evaluation with LogMAR BCVA (p = 0.01). The benefit was not found in patients with partial or no HBOT. Only one patient developed an episode of seizure while receiving HBOT; no complications occurred in the rest of the patients.
CONCLUSIONS: HBOT improves visual outcomes in CRAO patients who received an entire course of therapy. The benefit from HBOT does not improve the visual outcome in patients who receive partial or no treatment HBOT. Our results suggest that HBOT is safe and may be considered as a treatment option for patients with CRAO who present to the hospital within 24 h of symptom onset.
参考来源
- Orwig DM, Wang J, Li Z, et al. The effects of hyperbaric oxygen treatment for non-arteritic central retinal artery occlusion (HBOT-CRAO). Am J Emerg Med. 2025. PMID: 40784185. doi:10.1016/j.ajem.2025.07.065
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。